Found: 23
Select item for more details and to access through your institution.
The addition of FAIMS increases targeted proteomics sensitivity from FFPE tumor biopsies.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-16358-1
- By:
- Publication type:
- Article
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1577, doi. 10.1007/s10637-021-01138-x
- By:
- Publication type:
- Article
Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
- Published in:
- 2015
- By:
- Publication type:
- Erratum
Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with <i>MET</i> Gene Amplification in FFPE Tumor Tissue.
- Published in:
- PLoS ONE, 2014, v. 9, n. 7, p. 1, doi. 10.1371/journal.pone.0100586
- By:
- Publication type:
- Article
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
- Published in:
- PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0054014
- By:
- Publication type:
- Article
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-61957-9
- By:
- Publication type:
- Article
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling.
- Published in:
- Cancers, 2023, v. 15, n. 2, p. 460, doi. 10.3390/cancers15020460
- By:
- Publication type:
- Article
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-49867-7
- By:
- Publication type:
- Article
COMP-16. CORRELATING MGMT PROTEIN LEVEL WITH TEMOZOLOMIDE RESPONSE IN GLIOBLASTOMA PATIENTS USING MASS SPECTROMETRY.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi67, doi. 10.1093/neuonc/noy148.271
- By:
- Publication type:
- Article
Expression array analysis of the hepatocyte growth factor invasive program.
- Published in:
- Clinical & Experimental Metastasis, 2015, v. 32, n. 7, p. 659, doi. 10.1007/s10585-015-9735-0
- By:
- Publication type:
- Article
Immuno-PET of the Hepatocyte Growth Factor Receptor Met Using the 1-Armed Antibody Onartuzumab.
- Published in:
- Journal of Nuclear Medicine, 2012, v. 53, n. 10, p. 1592, doi. 10.2967/jnumed.111.102293
- By:
- Publication type:
- Article
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.
- Published in:
- International Journal of Cancer, 2019, v. 145, n. 3, p. 748, doi. 10.1002/ijc.32170
- By:
- Publication type:
- Article
Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.
- Published in:
- PLoS ONE, 2016, v. 11, n. 6, p. 1, doi. 10.1371/journal.pone.0157130
- By:
- Publication type:
- Article
Targeting the hepatocyte growth factor/Met pathway in cancer.
- Published in:
- Biochemical Society Transactions, 2017, v. 45, n. 4, p. 855, doi. 10.1042/BST20160132
- By:
- Publication type:
- Article
Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.
- Published in:
- Gastric Cancer, 2016, v. 19, n. 4, p. 1066, doi. 10.1007/s10120-015-0566-0
- By:
- Publication type:
- Article
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
- Published in:
- Journal of Neuro-Oncology, 2020, v. 146, n. 1, p. 163, doi. 10.1007/s11060-019-03358-x
- By:
- Publication type:
- Article
Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [<sup>99m</sup>Tc] (AH-113018) or Cy 5<sup>**</sup> (AH-112543) Labeled Peptide.
- Published in:
- Molecular Imaging, 2015, v. 14, p. 499, doi. 10.2310/7290.2015.00023
- By:
- Publication type:
- Article
Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [<sup>99m</sup>Tc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide.
- Published in:
- Molecular Imaging, 2015, v. 14, p. 499, doi. 10.2310/7290.2015.00023
- By:
- Publication type:
- Article
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.
- Published in:
- Molecular Oncology, 2016, v. 10, n. 1, p. 138, doi. 10.1016/j.molonc.2015.09.002
- By:
- Publication type:
- Article